Azacitidine

Generic Name
Azacitidine
Brand Names
Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
Drug Type
Small Molecule
Chemical Formula
C8H12N4O5
CAS Number
320-67-2
Unique Ingredient Identifier
M801H13NRU
Background

Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...

Indication

Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...

Associated Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
Associated Therapies
-
Clinical Trials
Related News

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

First Posted Date
2007-07-19
Last Posted Date
2016-06-09
Lead Sponsor
University of Miami
Target Recruit Count
22
Registration Number
NCT00503984
Locations
🇺🇸

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Phase 1
Completed
Conditions
Advanced Cancers
Interventions
Drug: Azacitidine
Drug: Valproic Acid
First Posted Date
2007-07-04
Last Posted Date
2012-08-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
69
Registration Number
NCT00496444
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

Phase 2
Terminated
Conditions
Myelodysplastic Syndrome
First Posted Date
2007-07-03
Last Posted Date
2014-04-07
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
16
Registration Number
NCT00495547
Locations
🇪🇸

Hospital del Mar, Barcelona, Spain

🇪🇸

Hospital la Paz, Madrid, Spain

🇪🇸

Hospital Clínic Universitari, Barcelona, Spain

and more 7 locations

AVIDA The Vidaza® (Azacitidine) Patient Registry

Completed
Conditions
Myelodysplastic Syndromes
First Posted Date
2007-06-01
Last Posted Date
2018-05-03
Lead Sponsor
Celgene
Target Recruit Count
479
Registration Number
NCT00481273
Locations
🇺🇸

AVIDA Registry Help, Kansas City, Missouri, United States

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 2
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2007-03-30
Last Posted Date
2013-08-26
Lead Sponsor
The University of New South Wales
Target Recruit Count
2000
Registration Number
NCT00454480
Locations
🇬🇧

Queen's Hospital, Burton-upon-Trent, England, United Kingdom

🇬🇧

Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom

🇬🇧

Hereford Hospitals, Hereford, United Kingdom

and more 93 locations

A Phase II Study of Maintenance With Azacitidine in MDS Patients

First Posted Date
2007-03-12
Last Posted Date
2012-01-19
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
39
Registration Number
NCT00446303
Locations
🇫🇷

CHU de Caen, Caen, France

🇫🇷

CHU d'Amiens, Amiens, France

🇫🇷

Hopital d'Instruction des Armées Percy, Clamart, France

and more 22 locations

Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1
Terminated
Conditions
Squamous Cell Carcinoma
Interventions
Drug: Azacitidine
Drug: Cisplatin
First Posted Date
2007-03-05
Last Posted Date
2017-02-27
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
1
Registration Number
NCT00443261
Locations
🇺🇸

Kansas City VA Medical Center, Kansas City, Missouri, United States

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
First Posted Date
2007-02-26
Last Posted Date
2018-08-07
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
62
Registration Number
NCT00439673
Locations
🇮🇹

Ospedale Reg. A di Summa, Brindisi, Italy

🇮🇹

Ospedale A. Businco, Cagliari, Italy

🇮🇹

Università degli studi di Roma La Cattolica, Roma, Italy

and more 4 locations

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Phase 2
Terminated
Conditions
Multiple Myeloma
First Posted Date
2006-12-19
Last Posted Date
2013-12-16
Lead Sponsor
Bayside Health
Target Recruit Count
7
Registration Number
NCT00412919
Locations
🇦🇺

The Alfred Hospital, Melbourne, Victoria, Australia

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Phase 2
Terminated
Conditions
Chronic Lymphocytic Leukemia
Leukemia
Interventions
Drug: 5-Azacytidine
First Posted Date
2006-12-19
Last Posted Date
2015-06-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
9
Registration Number
NCT00413478
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy